Report cover image

Global Women's Health Care Drugs Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 190 Pages
SKU # APRC20362056

Description

Summary

According to APO Research, The global Women's Health Care Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Women's Health Care Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Women's Health Care Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Women's Health Care Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Women's Health Care Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Women's Health Care Drugs include Merck & Co, Mylan N.V., Lupin, Pfizer Inc., Ferring Pharmaceuticals, Bayer AG, Amgen, Allergan and Blairex Laboratories, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Women's Health Care Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Women's Health Care Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Women's Health Care Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Women's Health Care Drugs revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Women's Health Care Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Women's Health Care Drugs revenue, projected growth trends, production technology, application and end-user industry.

Women's Health Care Drugs Segment by Company

Merck & Co
Mylan N.V.
Lupin
Pfizer Inc.
Ferring Pharmaceuticals
Bayer AG
Amgen
Allergan
Blairex Laboratories
Apothecus Pharmaceutical
Agile Therapeutics
Women's Health Care Drugs Segment by Type

Endometriosis
Postmenopausal Osteoporosis
Menopause
Hormonal Infertility
Polycystic Ovary Syndrome
Contraceptives
Others
Women's Health Care Drugs Segment by Application

Prescription Drugs
Non-prescription Drugs
Women's Health Care Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Women's Health Care Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Women's Health Care Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Women's Health Care Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Women's Health Care Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Women's Health Care Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Women's Health Care Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

190 Pages
1 Market Overview
1.1 Product Definition
1.2 Women's Health Care Drugs Market by Type
1.2.1 Global Women's Health Care Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Endometriosis
1.2.3 Postmenopausal Osteoporosis
1.2.4 Menopause
1.2.5 Hormonal Infertility
1.2.6 Polycystic Ovary Syndrome
1.2.7 Contraceptives
1.2.8 Others
1.3 Women's Health Care Drugs Market by Application
1.3.1 Global Women's Health Care Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Prescription Drugs
1.3.3 Non-prescription Drugs
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Women's Health Care Drugs Market Dynamics
2.1 Women's Health Care Drugs Industry Trends
2.2 Women's Health Care Drugs Industry Drivers
2.3 Women's Health Care Drugs Industry Opportunities and Challenges
2.4 Women's Health Care Drugs Industry Restraints
3 Global Growth Perspective
3.1 Global Women's Health Care Drugs Market Perspective (2020-2031)
3.2 Global Women's Health Care Drugs Growth Trends by Region
3.2.1 Global Women's Health Care Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Women's Health Care Drugs Market Size by Region (2020-2025)
3.2.3 Global Women's Health Care Drugs Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Women's Health Care Drugs Revenue by Players
4.1.1 Global Women's Health Care Drugs Revenue by Players (2020-2025)
4.1.2 Global Women's Health Care Drugs Revenue Market Share by Players (2020-2025)
4.1.3 Global Women's Health Care Drugs Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Women's Health Care Drugs Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Women's Health Care Drugs Key Players Headquarters & Area Served
4.4 Global Women's Health Care Drugs Players, Product Type & Application
4.5 Global Women's Health Care Drugs Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Women's Health Care Drugs Market CR5 and HHI
4.6.3 2024 Women's Health Care Drugs Tier 1, Tier 2, and Tier 3
5 Women's Health Care Drugs Market Size by Type
5.1 Global Women's Health Care Drugs Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Women's Health Care Drugs Revenue by Type (2020-2031)
5.3 Global Women's Health Care Drugs Revenue Market Share by Type (2020-2031)
6 Women's Health Care Drugs Market Size by Application
6.1 Global Women's Health Care Drugs Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Women's Health Care Drugs Revenue by Application (2020-2031)
6.3 Global Women's Health Care Drugs Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Merck & Co
7.1.1 Merck & Co Comapny Information
7.1.2 Merck & Co Business Overview
7.1.3 Merck & Co Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.1.4 Merck & Co Women's Health Care Drugs Product Portfolio
7.1.5 Merck & Co Recent Developments
7.2 Mylan N.V.
7.2.1 Mylan N.V. Comapny Information
7.2.2 Mylan N.V. Business Overview
7.2.3 Mylan N.V. Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.2.4 Mylan N.V. Women's Health Care Drugs Product Portfolio
7.2.5 Mylan N.V. Recent Developments
7.3 Lupin
7.3.1 Lupin Comapny Information
7.3.2 Lupin Business Overview
7.3.3 Lupin Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.3.4 Lupin Women's Health Care Drugs Product Portfolio
7.3.5 Lupin Recent Developments
7.4 Pfizer Inc.
7.4.1 Pfizer Inc. Comapny Information
7.4.2 Pfizer Inc. Business Overview
7.4.3 Pfizer Inc. Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.4.4 Pfizer Inc. Women's Health Care Drugs Product Portfolio
7.4.5 Pfizer Inc. Recent Developments
7.5 Ferring Pharmaceuticals
7.5.1 Ferring Pharmaceuticals Comapny Information
7.5.2 Ferring Pharmaceuticals Business Overview
7.5.3 Ferring Pharmaceuticals Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.5.4 Ferring Pharmaceuticals Women's Health Care Drugs Product Portfolio
7.5.5 Ferring Pharmaceuticals Recent Developments
7.6 Bayer AG
7.6.1 Bayer AG Comapny Information
7.6.2 Bayer AG Business Overview
7.6.3 Bayer AG Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.6.4 Bayer AG Women's Health Care Drugs Product Portfolio
7.6.5 Bayer AG Recent Developments
7.7 Amgen
7.7.1 Amgen Comapny Information
7.7.2 Amgen Business Overview
7.7.3 Amgen Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.7.4 Amgen Women's Health Care Drugs Product Portfolio
7.7.5 Amgen Recent Developments
7.8 Allergan
7.8.1 Allergan Comapny Information
7.8.2 Allergan Business Overview
7.8.3 Allergan Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.8.4 Allergan Women's Health Care Drugs Product Portfolio
7.8.5 Allergan Recent Developments
7.9 Blairex Laboratories
7.9.1 Blairex Laboratories Comapny Information
7.9.2 Blairex Laboratories Business Overview
7.9.3 Blairex Laboratories Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.9.4 Blairex Laboratories Women's Health Care Drugs Product Portfolio
7.9.5 Blairex Laboratories Recent Developments
7.10 Apothecus Pharmaceutical
7.10.1 Apothecus Pharmaceutical Comapny Information
7.10.2 Apothecus Pharmaceutical Business Overview
7.10.3 Apothecus Pharmaceutical Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.10.4 Apothecus Pharmaceutical Women's Health Care Drugs Product Portfolio
7.10.5 Apothecus Pharmaceutical Recent Developments
7.11 Agile Therapeutics
7.11.1 Agile Therapeutics Comapny Information
7.11.2 Agile Therapeutics Business Overview
7.11.3 Agile Therapeutics Women's Health Care Drugs Revenue and Gross Margin (2020-2025)
7.11.4 Agile Therapeutics Women's Health Care Drugs Product Portfolio
7.11.5 Agile Therapeutics Recent Developments
8 North America
8.1 North America Women's Health Care Drugs Revenue (2020-2031)
8.2 North America Women's Health Care Drugs Revenue by Type (2020-2031)
8.2.1 North America Women's Health Care Drugs Revenue by Type (2020-2025)
8.2.2 North America Women's Health Care Drugs Revenue by Type (2026-2031)
8.3 North America Women's Health Care Drugs Revenue Share by Type (2020-2031)
8.4 North America Women's Health Care Drugs Revenue by Application (2020-2031)
8.4.1 North America Women's Health Care Drugs Revenue by Application (2020-2025)
8.4.2 North America Women's Health Care Drugs Revenue by Application (2026-2031)
8.5 North America Women's Health Care Drugs Revenue Share by Application (2020-2031)
8.6 North America Women's Health Care Drugs Revenue by Country
8.6.1 North America Women's Health Care Drugs Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Women's Health Care Drugs Revenue by Country (2020-2025)
8.6.3 North America Women's Health Care Drugs Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Women's Health Care Drugs Revenue (2020-2031)
9.2 Europe Women's Health Care Drugs Revenue by Type (2020-2031)
9.2.1 Europe Women's Health Care Drugs Revenue by Type (2020-2025)
9.2.2 Europe Women's Health Care Drugs Revenue by Type (2026-2031)
9.3 Europe Women's Health Care Drugs Revenue Share by Type (2020-2031)
9.4 Europe Women's Health Care Drugs Revenue by Application (2020-2031)
9.4.1 Europe Women's Health Care Drugs Revenue by Application (2020-2025)
9.4.2 Europe Women's Health Care Drugs Revenue by Application (2026-2031)
9.5 Europe Women's Health Care Drugs Revenue Share by Application (2020-2031)
9.6 Europe Women's Health Care Drugs Revenue by Country
9.6.1 Europe Women's Health Care Drugs Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Women's Health Care Drugs Revenue by Country (2020-2025)
9.6.3 Europe Women's Health Care Drugs Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Women's Health Care Drugs Revenue (2020-2031)
10.2 China Women's Health Care Drugs Revenue by Type (2020-2031)
10.2.1 China Women's Health Care Drugs Revenue by Type (2020-2025)
10.2.2 China Women's Health Care Drugs Revenue by Type (2026-2031)
10.3 China Women's Health Care Drugs Revenue Share by Type (2020-2031)
10.4 China Women's Health Care Drugs Revenue by Application (2020-2031)
10.4.1 China Women's Health Care Drugs Revenue by Application (2020-2025)
10.4.2 China Women's Health Care Drugs Revenue by Application (2026-2031)
10.5 China Women's Health Care Drugs Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Women's Health Care Drugs Revenue (2020-2031)
11.2 Asia Women's Health Care Drugs Revenue by Type (2020-2031)
11.2.1 Asia Women's Health Care Drugs Revenue by Type (2020-2025)
11.2.2 Asia Women's Health Care Drugs Revenue by Type (2026-2031)
11.3 Asia Women's Health Care Drugs Revenue Share by Type (2020-2031)
11.4 Asia Women's Health Care Drugs Revenue by Application (2020-2031)
11.4.1 Asia Women's Health Care Drugs Revenue by Application (2020-2025)
11.4.2 Asia Women's Health Care Drugs Revenue by Application (2026-2031)
11.5 Asia Women's Health Care Drugs Revenue Share by Application (2020-2031)
11.6 Asia Women's Health Care Drugs Revenue by Country
11.6.1 Asia Women's Health Care Drugs Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Women's Health Care Drugs Revenue by Country (2020-2025)
11.6.3 Asia Women's Health Care Drugs Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Women's Health Care Drugs Revenue (2020-2031)
12.2 SAMEA Women's Health Care Drugs Revenue by Type (2020-2031)
12.2.1 SAMEA Women's Health Care Drugs Revenue by Type (2020-2025)
12.2.2 SAMEA Women's Health Care Drugs Revenue by Type (2026-2031)
12.3 SAMEA Women's Health Care Drugs Revenue Share by Type (2020-2031)
12.4 SAMEA Women's Health Care Drugs Revenue by Application (2020-2031)
12.4.1 SAMEA Women's Health Care Drugs Revenue by Application (2020-2025)
12.4.2 SAMEA Women's Health Care Drugs Revenue by Application (2026-2031)
12.5 SAMEA Women's Health Care Drugs Revenue Share by Application (2020-2031)
12.6 SAMEA Women's Health Care Drugs Revenue by Country
12.6.1 SAMEA Women's Health Care Drugs Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Women's Health Care Drugs Revenue by Country (2020-2025)
12.6.3 SAMEA Women's Health Care Drugs Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.